Screen2Prevent (S2P) HIV Screening Study

This study, called Screen2Prevent (S2P), is looking at different ways to screen young people for HIV in emergency departments (EDs). It aims to find the best approach to identify HIV infections and quickly connect patients to HIV Pre-Exposure Prophylaxis (PrEP), a medicine to prevent HIV, or Antiretroviral Treatment (ART), medicines to treat HIV. The study will test three different screening strategies: targeted screening (for those at higher risk), universally offered opt-in screening (where everyone is offered a test and can choose to take it), and universally offered opt-out screening (where everyone is offered a test unless they say no). Researchers will measure how many new HIV cases are found each month and how quickly PrEP/ART is started after an ED visit. You can join if you are between 14 and 24 years old and visit a participating ED.

Study design
This interventional study will test three different HIV screening strategies, each for 8 months, over a total of 24 months. It plans to enroll 84,000 participants.
What's involved
You would be offered a computerized sexual health survey on a tablet during your ED visit. You can choose whether or not to complete the survey.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes related to HIV detection and PrEP/ART initiation at 36 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07728123

Screen2Prevent (S2P)

Recruiting
NAAges 14–24InterventionalScreening
Westat
~84,000 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:HIV screening strategies

At a glance

Recruiting sites
2 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Monthly HIV detection rates per 1,000 eligible patients
Measured over 36 months
+1 more outcome measured
HIV Infections
5 sites across 5 states
Florida1
Georgia1
Maryland1
Tennessee1
Texas1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 14-24 years, inclusive
Present to the participating ED, regardless of chief complaint during the study period

Exclusion

None
  • Monthly HIV detection rates per 1,000 eligible patients36 months

    Compare the rate of HIV detection between each screening strategy (targeted, universal opt-in, universal opt-out) to baseline using the all patients analysis set.

  • Rapid PrEP/ART initiation (defined by prescription within 72 hours of ED discharge)36 months

    Compare the rates of rapid start of PrEP/ART, defined as PrEP/ART prescription within 72 hours of ED discharge, between adolescents and young adults who visit the ED prior to implementation of cSHS and those who visit after implementation of cSHS using the all patients analysis set.